Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // September 19th, 2011 // 7:00 am
Good morning, everyone, and how are you today? We hope the weekend was relaxing and refreshing. Now, though, the time has come to resume that routine of meetings and deadlines that will make the hours fly by. We share your plight. We have much to do today. To cope, we are brewing another cup of stimulation. Meanwhile, here are some tidbits from around that great, big pharma universe. And keep us in mind if you hear of something else that appears interesting. Hope today goes well…
Amgen Wins Added Indications For Prolia (Bloomberg News)
Merck Serono Buys An MS Drug (Globes)
Stada Eyes Part Of Glaxo OTC Portfolio (Reuters)
NIH To Develop A Chip To Test For Drug Toxicity (MSNBC)
Over-Prescribing Meds Is Chronic In Europe: Study (Pharma Times)
Abbott M&A And Emerging Markets (The Deal)
Sanofi Wins US Patent Ruling On Eloxatin Cancer Drug (Reuters)
Bristol-Myers Hepatitis C Drug Had High Cure Rate In Study (Bloomberg News)
Sun Pharma Resolves Manufacuring Issues With FDA (Economic Times)
The UN, Non-Communicable Diseases And Patents (New York Times)
Sudden Death In Epilepsy Drops With Drug Treatment (MedPage Today)
J&J Negotiated Over Executive’s Departure (Wall Street Journal)
Biogen Investors Bet On Results Of MS Drug Trial (Reuters)
Polish Pharma To Buy Largest Drugmaker In Kazakhstan (Silk Road Intelligencer)
EDITOR’S NOTE: Please check this post for updates throughout the morning
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Abbott Laboratories, Amgen, Biogen, Boston Scientific, Bristol Myers Squibb, Eloxatin, Epilepsy, Europe, FDA, GlaxoSmithKline, Hepatitis C, JJ, Johnson & Johnson, Kazakhstan, Merck-Serono, MS, Multiple Sclerosis, National Institutes of Health, NIH, Non-Communicable Diseases, OTC, Overprescribing, Patents, Poland, Prolia, Sanofi, Stada, Sudden Deanth, Sun Pharma, Toxicity